Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Olaparib is a potent PARP inhibitor (PARP1, 2, and 3) that is being developed as a monotherapy as well as for combination with chemotherapy, ionizing radiation, and other anti-cancer agents including novel agents and immunotherapy. Paclitaxel is widely used in breast, lung and gastric cancer with every 3-week o

Trial Details

NCT ID
NCT04592211
Phase
PHASE1 / PHASE2
Sponsor
Yonsei University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • olaparib+pembrolizumab+paclitaxel
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Provided written informed consent for treatment.
  • Age ≥ 19 years old
  • measurable or evaluable disease based on RECIST 1.1. Lesions
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 on time of patient's allocation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →